drugset
Drugs / EBV-TCR-T (YT-E001)
last change Oct 2021 re-read 3 minutes ago

EBV-TCR-T (YT-E001)

Cell therapy

Developed for
nasopharyngeal carcinoma
Investigated by
China Immunotech (Beijing) Biotechnology Co., Ltd. · Fujian Cancer Hospital

Trials 1

today NCT03648697 · Ph 2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03648697 Oct 2018 → Oct 2021 nasopharyngeal carcinoma Fujian Cancer Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EBV-TCR-T (YT-E001) ClinicalTrials.gov intervention name — accepted as the source's own label NCT03648697 ↗
Action Deplete “We want to see if EBV antigen special T cells (YT-E001) could recognize and kill special parts of EBV infected cells” NCT03648697 ↗
Modality Cell therapy “TCR-T cell therapy” NCT03648697 ↗
Route Intravenous “A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered.” NCT03648697 ↗